TY -的T1 -一项随机,双盲,对照试验的静脉< em > <跨类= "强调" >我< / span > < / em > mmunoglobulins与静脉< em > <跨类=“下划线”> M < / span > < / em > ethylprednisolone在< em > <跨类=“下划线”> C < / span > < / em > hronic炎性脱髓鞘多神经根神经病< em >研究(IMC) < / em > (S07.001) JF -神经学乔-神经病学SP - S07.001 LP - S07.001六世- 78 - 1补充AU -爱德华多Nobile-Orazio AU -达里奥Cocito AU -斯特凡诺Jann盟Antonino Uncini AU首页 -埃托雷Beghi AU -乔瓦尼Antonini盟Raffaella法齐奥盟-弗朗西斯卡高卢盟安吉洛Schenone AU - Ada地区非盟-大卫。Pareyson盟卢西奥澳网AU -斯特凡诺Tamburin AU -罗伯塔马基群落盟把拉出的非盟-圭多Cavaletti AU -法比奥Giannini盟马里奥Sabatelli Y1 - 2012/04/24 UR - //www.ez-admanager.com/content/78/1_Supplement/S07.001.abstract N2 -目的:比较6个月治疗的有效性和安全性与静脉注射免疫球蛋白(丙种球蛋白)或甲基强的松龙(IVMP)在慢性炎性脱髓鞘多神经根神经病(CIDP)。背景丙种球蛋白和类固醇作为初始治疗同样有效在CIDP但鲜为人知的相对风险长时间剖面。设计/方法:46个病人实现外汇/ pn标准明确的CIDP被随机分配在一个1:1比例获得丙种球蛋白(IgVena Kedrion SpA) (2 g / kg) + IVMP-placebo或IVMP (2 g) + IVIg-placebo超过四天,每月为六个月。患者随后6个月评估复发。主要终点是不同数量的患者暂停丙种球蛋白或IVMP不耐受或无效。二级终端包括改善评估尺度的差异后15天,2个月和6个月的治疗,病人的比例的差异治疗停药后恶化。结果:45例(24 IVMP丙种球蛋白和21)进行评估。一个是不适当的夹杂物排除在外。更多的病人停止IVMP(10/21, 52.5%)比丙种球蛋白(3/24,12.5%)(p = 0, 0085),反应迟钝或不耐受疗法。最后6个月治疗,两组同样改善了Rankin,辊筒、鹿特丹和SF-36生活质量量表和丙种球蛋白组也在湄公河委员会和感官评分和时间走10米。丙种球蛋白治疗停药后更多的病人(8/21,38.1%)比IVMP(0/10)恶化,需要进一步的治疗。到12个月,一个类似的比例仍然没有改善的患者治疗的丙种球蛋白(13/24,54.1%)和IVMP (10/21, 47.6%)。Conclusions: More patients on IVMP than on IVIg suspended therapy during the six months of therapy because of inefficacy or adverse events. After therapy discontinuation, more patients treated with IVIg than with IVMP worsened and had to resume therapy.Supported by: Kedrion SpA, Italy.Disclosure: Dr. Nobile-Orazio has received personal compensation for activities with CSL Behring. Dr. Cocito has nothing to disclose. Dr. Jann has nothing to disclose. Dr. Uncini has nothing to disclose. Dr. Beghi has received personal compensation for activities with UCB Pharma as a speaker. Dr. Beghi has received personal compensation in an editorial capacity for Epilepsia. Dr. Antonini has nothing to disclose. Dr. Fazio has nothing to disclose. Dr. Gallia has nothing to disclose. Dr. Schenone has nothing to disclose. Dr. Francia has nothing to disclose. Dr. Pareyson has nothing to disclose. Dr. Santoro has nothing to disclose. Dr. Tamburin has nothing to disclose. Dr. Macchia has received personal compensation for activities with Kedrion as an employee. Dr. Guarneri has received personal compensation for activities with Kedrion Biopharmaceutical an employee. Dr. Cavaletti has nothing to disclose. Dr. Giannini has nothing to disclose. Dr. Sabatelli has nothing to disclose. Tuesday, April 24 2012, 13:00 pm-14:45 pm ER -